Implements product-first strategy and realigns operations around core properties TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a digital publisher focused on building tools, platforms, and experiences for gamers, today announced financial results for the three months ended June 30, 2025 (“Q2 2025”). “We are a company of builders and our future will be shaped by the tools, platforms, and experiences we own, and by the tens of millions of gamers who rely on them,” said Alex Macdonald, CEO of Enthusiast Gaming. “We know exactly what we do best, which is deliver products that elevate performance, deepen engagement, and make every moment of play more meaningful. Our portfolio is made up of many category leaders including U.GG, Icy-Veins, TheSimsResource,...

Quarterly net revenues were RMB706.4 million (US$98.6 million)1Quarterly lidar shipments were 352,095 unitsQuarterly net income was RMB44.1 million (US$6.2 million) SHANGHAI, China, Aug. 14, 2025 (GLOBE NEWSWIRE) — Hesai Group (“Hesai” or the “Company”), (NASDAQ: HSAI), the global leader in three-dimensional light detection and ranging (lidar) solutions, today announced its unaudited financial results for the three months ended June 30, 2025. Management Remarks “The second quarter marked a surge in our growth momentum with net revenues soaring over 50% year-over-year and net income exceeding RMB40 million, beating our GAAP breakeven target—powered by strong customer demand and sharp operational execution,” said Yifan “David” Li, Hesai’s Co-Founder and CEO. “In ADAS, the ‘Hesai Inside’ label is now widely recognized as a mark of...

Total SUI Holdings of 81.9 Million as of August 10, 2025, Underscoring Mill City’s Market Leadership WAYZATA, Minn., Aug. 14, 2025 (GLOBE NEWSWIRE) — Mill City Ventures III, Ltd. (“Mill City” or the “Company”) (NASDAQ: MCVT) today announced financial and operating results for the three months ended June 30, 2025, from its legacy commercial short-term non-bank lending and specialty finance business. The Company is also providing an update on recent developments, including its launch of the first publicly traded, Foundation-backed SUI treasury strategy on July 31, 2025, and subsequent events. The Company intends to continue its existing commercial short-term non-bank lending and specialty finance business. Since launching the industry’s first SUI treasury strategy, under which the principal holding in Mill City’s treasury reserve...

TORTOLA, British Virgin Islands, Aug. 14, 2025 (GLOBE NEWSWIRE) — Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announces that it has filed its condensed consolidated interim financial statements and management’s discussion and analysis for the three and six month periods ended June 30, 2025 (“Q2 2025“) with the Canadian securities regulatory authorities. All amounts are in United States dollars (“$”) unless otherwise stated. Jay Lyons, Chief Executive Officer, commented: “Operationally, Orca continues to perform in line with expectations, delivering a 9% increase in daily gas sold, compared with Q2 2024. We continue to see robust demand from our industrial customers, with sales growing in excess of 40% from H1 2024. I am also pleased...

Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million Accepted as a new member of U.S. Medical CBRN Defense Consortium, strengthening government and biodefense partnershipsHALIFAX, Nova Scotia, Aug. 14, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the first quarter of its fiscal year 2026, which ended on June 30, 2025. All figures are in Canadian dollars unless otherwise stated. “Appili continues to strengthen our position within government and biodefense industries, highlighted by our recent participation in the U.S. Medical CBRN Defense...

KAPALUA, Hawai‘i, Aug. 14, 2025 (GLOBE NEWSWIRE) — Maui Land & Pineapple Company, Inc. (NYSE: MLP) today reported financial results covering the quarter ended June 30, 2025. “The Company’s strong financial performance and significant revenue growth in the first half of 2025 validate our path to unlock value by maximizing the productivity of our land and commercial properties,” said Race Randle, CEO, Maui Land & Pineapple Company, Inc. “We continue to resolve legacy responsibilities and market non-strategic parcels for sale to fund projects and land improvements. Throughout the second quarter, we intentionally deployed capital to grow and diversify revenue streams, including the investment in materials and labor to launch our agave venture by planting blue weber agave on underutilized croplands in Upcounty, Maui. In addition,...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), a leading provider of wellness solutions for people on the go, today announced results for the second quarter ended June 30, 2025. From providing critical biosecurity support to building tech-forward wellness spaces in transportation hubs and local communities, XWELL currently is on a growth trajectory. Through its portfolio of in-airport and off-airport brands, the Company is reimagining what it means to access wellness. Operating HighlightsRevenue for the 2025 second quarter totaled $7.7 million Cost of sales decreased approximately 5% from the 2024 second quarter General and administrative expenses decreased by approximately 9% from the 2024 second quarter Named the official wellness spa of the Orlando...

BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments. “During our second quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “We have now finalized our study protocol, and we expect to initiate our Phase 2b clinical study of IKT-001, our re-engineered prodrug of imatinib mesylate, in PAH in the second half of 2025.” Multiple studies including both Phase 2 and the Phase 3 IMPRES...

PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-year Invivyd’s target of near-term profitability (1H 2025) was not met but remains possible with the upcoming respiratory virus season Announced alignment with U.S. FDA on rapid pathway to full approval (BLA) of vaccine alternative monoclonal antibody candidate VYD2311 to protect American adults and adolescents from COVID-19 Announced attractive safety profile and pharmacokinetics data for VYD2311 from our pre-pivotal first-in-human clinical trial, including 76-day observed half-life for IM route of administration, allowing for potential long-term protectionWALTHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended June 30, 2025, and provided...

FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today provided business updates. FDA Discussions & Roluperidone Update The Company has had multiple interactions with the FDA following receipt of the Complete Response Letter (CRL) for its New Drug Application (NDA) in February 2024 and the FDA has confirmed the requirement for an additional confirmatory clinical trial to address the deficiencies cited in the CRL and resubmit the NDA. As in the two previous studies (C03 and C07), the required confirmatory...